{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ruiz-Irastorza G"],"funding":["Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza"],"pagination":["e001562"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12107586"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["<h4>Objective</h4>To assess the efficacy and toxicity of the Lupus-Cruces Nephritis (LCN) protocol compared with standard of care (SOC) with cyclophosphamide (CYC) or mycophenolate in patients with lupus nephritis (LN) during an extended follow-up time up to 10 years.<h4>Methods</h4>Patients with biopsy-proven class III, IV or V LN treated with LCN were compared with SOC. Patients in the LCN were treated with a CYC plus repeated methylprednisolone pulse-based regimen. The achievement of complete renal response (CRR) and the progression to chronic kidney disease (CKD) were the two main outcomes. Glucocorticoid (GC)-related toxicity, major infections and damage accrual were also analysed. A propensity score (PS)-adjusted multivariate analysis was used to overcome the confounding-by-indicatio"],"journal":["Lupus science & medicine"],"pubmed_title":["Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts."],"pmcid":["PMC12107586"],"funding_grant_id":["IT 1512-22"],"pubmed_authors":["Ruiz-Irastorza G","Paredes Ruiz D","Osorio A","Marin-Garcia B","Duena-Bartolome L","Lazaro E"],"additional_accession":[]},"is_claimable":false,"name":"Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts.","description":"<h4>Objective</h4>To assess the efficacy and toxicity of the Lupus-Cruces Nephritis (LCN) protocol compared with standard of care (SOC) with cyclophosphamide (CYC) or mycophenolate in patients with lupus nephritis (LN) during an extended follow-up time up to 10 years.<h4>Methods</h4>Patients with biopsy-proven class III, IV or V LN treated with LCN were compared with SOC. Patients in the LCN were treated with a CYC plus repeated methylprednisolone pulse-based regimen. The achievement of complete renal response (CRR) and the progression to chronic kidney disease (CKD) were the two main outcomes. Glucocorticoid (GC)-related toxicity, major infections and damage accrual were also analysed. A propensity score (PS)-adjusted multivariate analysis was used to overcome the confounding-by-indicatio","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2025-07-26T03:06:03.771Z","creation":"2025-07-26T03:06:03.771Z"},"accession":"S-EPMC12107586","cross_references":{"pubmed":["40425263"],"doi":["10.1136/lupus-2025-001562"]}}